- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06772623
Um estudo para avaliar os eventos adversos, a eficácia e a dose ideal de telisotuzumabe adizutecano intravenoso (IV) em combinação com budigalimabe intravenoso em participantes adultos com NSCLC não escamoso avançado ou metastático, sem tratamento prévio para doença avançada e sem alterações genômicas acionáveis
Um estudo aberto de multicoorte de fase 1b/2 para avaliar a segurança, eficácia e dose ideal de telisotuzumabe adizutecano em combinação com budigalimabe em NSCLC não escamoso avançado ou metastático, sem tratamento prévio para doença avançada e sem alterações genômicas acionáveis
Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) immune checkpoint inhibitor to adult participants to treat NSCLC.
Telisotuzumab Adizutecan (ABBV-400) and budigalimab are investigational drugs being developed for the treatment of NSCLC. This study will be divided into two stages, with the first stage treating participants with several doses of telisotuzumab adizutecan in combination with budigalimab within the dose escalation regimen until the dose reached is tolerable and expected to be efficacious. In Stage 2 there will be 3 treatment groups. Two groups will receive pembrolizumab with different optimized doses of telisotuzumab adizutecan (to allow for the best dose to be studied in the future). One group will receive the standard of care (SOC) - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. Approximately 252 adult participants with NSCLC will be enrolled in the study in 132 sites worldwide.
In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of Telisotuzumab Adizutecan in combination with budigalimab until the dose of Telisotuzumab Adizutecan reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive IV optimized doses of Telisotuzumab Adizutecan in combination with IV pembrolizumab, or IV SOC - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. The study will run for a duration of approximately 33 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Visão geral do estudo
Status
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: ABBVIE CALL CENTER
- Número de telefone: 844-663-3742
- E-mail: abbvieclinicaltrials@abbvie.com
Locais de estudo
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, Alemanha, 79106
- Recrutamento
- Universitaetsklinikum Freiburg /ID# 268473
-
Heilbronn, Baden-Wurttemberg, Alemanha, 74078
- Recrutamento
- Slk-Kliniken Heilbronn /ID# 269621
-
-
Bavaria
-
Augsburg, Bavaria, Alemanha, 86150
- Recrutamento
- Hamatologie-Onkologie im Zentrum MVZ GmbH /ID# 273043
-
Würzburg, Bavaria, Alemanha, 97080
- Recrutamento
- Universitaetsklinikum Wuerzburg /ID# 275445
-
-
Hesse
-
Frankfurt am Main, Hesse, Alemanha, 60590
- Recrutamento
- Universitaetsklinikum Frankfurt /ID# 268721
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Alemanha, 50937
- Recrutamento
- Universitaetsklinikum Koeln /ID# 268489
-
Hemer, North Rhine-Westphalia, Alemanha, 58675
- Recrutamento
- Lungenklinik Hemer /ID# 269779
-
-
Schleswig-Holstein
-
Oldenburg in Holstein, Schleswig-Holstein, Alemanha, 23758
- Recrutamento
- ohO Research GmbH /ID# 273060
-
-
Thuringia
-
Jena, Thuringia, Alemanha, 07747
- Recrutamento
- Universitatsklinikum Jena /ID# 269700
-
-
-
-
-
Buenos Aires, Argentina, 1426
- Recrutamento
- Centro Oncologico Korben /ID# 281460
-
Buenos Aires, Argentina, 1426
- Recrutamento
- Fundacion Respirar /ID# 281039
-
-
Buenos Aires
-
Mar del Plata, Buenos Aires, Argentina, 7600
- Recrutamento
- Clinca Colon /ID# 281465
-
-
Buenos Aires F.D.
-
Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentina, 1426
- Recrutamento
- Instituto Alexander Fleming /ID# 282704
-
-
-
-
New South Wales
-
Blacktown, New South Wales, Austrália, 2148
- Recrutamento
- Blacktown Hospital /ID# 281588
-
-
Queensland
-
Townsville, Queensland, Austrália, 4814
- Recrutamento
- Townsville University Hospital /ID# 281498
-
-
South Australia
-
Elizabeth Vale, South Australia, Austrália, 5112
- Recrutamento
- Lyell Mcewin Hospital /ID# 281860
-
-
Victoria
-
Frankston, Victoria, Austrália, 3199
- Recrutamento
- Peninsula University Hospital /ID# 281824
-
-
-
-
-
Liège, Bélgica, 4000
- Recrutamento
- Groupe Sante CHC - Clinique du MontLegia /ID# 271760
-
-
Limburg
-
Hasselt, Limburg, Bélgica, 3500
- Recrutamento
- Jessa Ziekenhuis - Campus Virga Jesse /ID# 268573
-
-
Oost-Vlaanderen
-
Sint-Niklaas, Oost-Vlaanderen, Bélgica, 9100
- Recrutamento
- Vitaz /Id# 280187
-
-
West-Vlaanderen
-
Roeselare, West-Vlaanderen, Bélgica, 8800
- Recrutamento
- AZ-Delta. /ID# 272433
-
-
-
-
Region Metropolitana Santiago
-
Santiago, Region Metropolitana Santiago, Chile, 8330032
- Recrutamento
- Pontificia Universidad Catolica De Chile /ID# 281594
-
Vitacura, Region Metropolitana Santiago, Chile, 7650027
- Recrutamento
- Oncored /Id# 281108
-
-
Santiago Metropolitan
-
Santiago, Santiago Metropolitan, Chile, 6900941
- Recrutamento
- Fundacion Arturo Lopez Perez /ID# 281211
-
Santiago, Santiago Metropolitan, Chile, 7500713
- Recrutamento
- Orlandi Oncologia /ID# 281132
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100021
- Recrutamento
- Cancer Hospital - Chinese Academy of Medical Sciences /ID# 269715
-
-
Fujian
-
Fuzhou, Fujian, China, 350014
- Recrutamento
- Fujian Province Cancer Hospital /ID# 269150
-
-
Guangxi
-
Liuzhou, Guangxi, China, 545006
- Recrutamento
- Liuzhou People's hospital /ID# 269667
-
-
Henan
-
Zhengzhou, Henan, China, 450008
- Recrutamento
- Henan Cancer Hospital /ID# 269668
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Recrutamento
- Union Hospital - Tongji Medical College /ID# 272286
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Recrutamento
- Hunan Province Cancer Hospital /ID# 269679
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Recrutamento
- Nanjing Drum Tower Hospital /ID# 269762
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330209
- Recrutamento
- The First Affiliated Hospital of Nanchang University - Xianghu Campus /ID# 269190
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710061
- Recrutamento
- The First Affiliated Hospital of Xi'an Jiaotong University /ID# 271904
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200030
- Recrutamento
- Shanghai Chest Hospital /ID# 269155
-
Shanghai, Shanghai Municipality, China, 200433
- Recrutamento
- Shanghai Pulmonary Hospital /ID# 276397
-
-
Shanxi
-
Taiyuan, Shanxi, China, 030001
- Recrutamento
- First Affiliated Hospital of Shanxi Medical University /ID# 276482
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Recrutamento
- West China Hospital of Sichuan University /ID# 270244
-
Chengdu, Sichuan, China, 610041
- Recrutamento
- Sichuan Province Cancer Hospital /ID# 269712
-
-
Yunnan
-
Kunming, Yunnan, China, 650106
- Recrutamento
- Yunnan Province Cancer Hospital /ID# 272331
-
-
-
-
-
A Coruña, Espanha, 15006
- Recrutamento
- Complejo Hospitalario Universitario A Coruna /ID# 271456
-
Alicante, Espanha, 03010
- Recrutamento
- Hospital General Universitario de Alicante /ID# 271316
-
Barcelona, Espanha, 08036
- Recrutamento
- Hospital Clinic de Barcelona /ID# 271452
-
Barcelona, Espanha, 08041
- Recrutamento
- Hospital Santa Creu i Sant Pau /ID# 271311
-
Barcelona, Espanha, 08003
- Recrutamento
- Hospital del Mar /ID# 271310
-
Málaga, Espanha, 29010
- Recrutamento
- Hospital Universitario Virgen de la Victoria /ID# 271312
-
-
Cantabria
-
Santander, Cantabria, Espanha, 39008
- Recrutamento
- Hospital Universitario Marques de Valdecilla /ID# 271314
-
-
Sevilla
-
Seville, Sevilla, Espanha, 41009
- Recrutamento
- Hospital Universitario Virgen Macarena /ID# 271447
-
-
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85054
- Ativo, não recrutando
- Mayo Clinic Hospital - Phoenix /ID# 272971
-
-
California
-
Fullerton, California, Estados Unidos, 92835
- Recrutamento
- Providence - St. Jude Medical Center /ID# 271414
-
Oxnard, California, Estados Unidos, 93030
- Recrutamento
- FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 274450
-
Santa Monica, California, Estados Unidos, 90404
- Recrutamento
- UCLA - Santa Monica /ID# 271690
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Recrutamento
- University Of Colorado - Anschutz Medical Campus /ID# 269069
-
Lone Tree, Colorado, Estados Unidos, 80124
- Recrutamento
- Rocky Mountain Cancer Centers - Lone Tree /ID# 272603
-
-
Florida
-
Jacksonville, Florida, Estados Unidos, 32224
- Recrutamento
- Mayo Clinic Hospital Jacksonville /ID# 275073
-
Orange City, Florida, Estados Unidos, 32763
- Recrutamento
- Mid Florida Hematology And Oncology Center /ID# 273777
-
-
Illinois
-
Hinsdale, Illinois, Estados Unidos, 60521
- Recrutamento
- Hope And Healing Cancer Services /ID# 276223
-
Contato:
- Site Coordinator
- Número de telefone: 6305600121
-
-
Indiana
-
Fort Wayne, Indiana, Estados Unidos, 46845
- Recrutamento
- Parkview Comprehensive Cancer Center /ID# 271879
-
Indianapolis, Indiana, Estados Unidos, 46202
- Concluído
- Community Health Network /ID# 273437
-
-
Kansas
-
Overland Park, Kansas, Estados Unidos, 66210
- Recrutamento
- Kansas City Cancer Center /ID# 273679
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Recrutamento
- Dana-Farber Cancer Institute /ID# 278417
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48202
- Recrutamento
- Henry Ford Hospital - Detroit /ID# 271642
-
-
Minnesota
-
Duluth, Minnesota, Estados Unidos, 55805
- Recrutamento
- St. Luke'S /ID# 273344
-
Rochester, Minnesota, Estados Unidos, 55905
- Recrutamento
- Mayo Clinic-Rochester /ID# 274512
-
-
New Jersey
-
East Brunswick, New Jersey, Estados Unidos, 08816-4096
- Recrutamento
- Astera Cancer Care /ID# 271915
-
-
New York
-
Shirley, New York, Estados Unidos, 11967
- Recrutamento
- New York Cancer And Blood Specialists - Shirley /ID# 272547
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44106
- Concluído
- University Hospitals Cleveland Medical Center /ID# 271726
-
Columbus, Ohio, Estados Unidos, 43219
- Recrutamento
- The Mark H Zangmeister Center /ID# 272502
-
-
Pennsylvania
-
Easton, Pennsylvania, Estados Unidos, 18045
- Recrutamento
- Spoknwrd Clinical Trials /ID# 273776
-
Contato:
- Site Coordinator
- Número de telefone: 610-813-2087
-
-
Texas
-
Houston, Texas, Estados Unidos, 77090
- Concluído
- Millennium Physicians /ID# 271717
-
Lubbock, Texas, Estados Unidos, 79410-1121
- Recrutamento
- Joe Arrington Cancer Research /ID# 272776
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84112
- Recrutamento
- Huntsman Cancer Institute /ID# 271686
-
-
Virginia
-
Leesburg, Virginia, Estados Unidos, 20176
- Recrutamento
- Virgnia Cancer Specialists /ID# 269633
-
-
Washington
-
Olympia, Washington, Estados Unidos, 98506
- Recrutamento
- Vista Oncology - East Olympia /ID# 275438
-
Tacoma, Washington, Estados Unidos, 98405
- Recrutamento
- Northwest Medical Specialties Tacoma /ID# 270469
-
-
-
-
Gironde
-
Bordeaux, Gironde, França, 33000
- Recrutamento
- Institut Bergonie /ID# 258377
-
-
Loire-Atlantique
-
Saint-Herblain, Loire-Atlantique, França, 44800
- Recrutamento
- CHU Nantes - Hopital Laennec /ID# 268475
-
Saint-Herblain, Loire-Atlantique, França, 44805
- Recrutamento
- Institut de Cancerologie de l'Ouest Rene Gauducheau /ID# 268484
-
-
Occitanie
-
Montpellier, Occitanie, França, 34070
- Recrutamento
- Centre De Cancerologie Du Grand Montpellier /ID# 273724
-
-
Provence-Alpes-Côte d'Azur Region
-
Nice, Provence-Alpes-Côte d'Azur Region, França, 06189
- Recrutamento
- Centre Antoine-Lacassagne /ID# 268486
-
-
Val-de-Marne
-
Villejuif, Val-de-Marne, França, 94805
- Recrutamento
- Institut Gustave Roussy /ID# 258373
-
-
Île-de-France Region
-
Paris, Île-de-France Region, França, 75248
- Recrutamento
- Institut Curie /ID# 271395
-
-
-
-
-
Bologna, Itália, 40138
- Recrutamento
- IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 268675
-
-
Forlì-Cesena
-
Meldola, Forlì-Cesena, Itália, 47014
- Recrutamento
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST - IRCCS /ID# 268684
-
-
Milano
-
Milan, Milano, Itália, 20121
- Recrutamento
- Istituto Europeo Di Oncologia /Id# 268670
-
-
Roma
-
Rome, Roma, Itália, 00144
- Recrutamento
- IRCCS Istituti Fisioterapici Ospitalieri-Istituto Nazionale Tumori Regina Elena /ID# 268626
-
Rome, Roma, Itália, 00184
- Recrutamento
- Azienda Ospedaliera Complesso Ospedaliero San Giovanni-Addolorata /ID# 273438
-
-
The Marches
-
Ancona, The Marches, Itália, 60126
- Recrutamento
- Azienda Ospedaliero Universitaria delle Marche /ID# 268667
-
-
Torino
-
Orbassano, Torino, Itália, 10043
- Recrutamento
- Azienda Ospedaliero Universitaria San Luigi Gonzaga /ID# 268641
-
-
-
-
-
Nagasaki, Japão, 852-8501
- Recrutamento
- Nagasaki University Hospital /ID# 273310
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japão, 460-0001
- Recrutamento
- NHO Nagoya Medical Center /ID# 272515
-
Nagoya, Aichi-ken, Japão, 464-8681
- Recrutamento
- Aichi Cancer Center /ID# 271978
-
-
Aomori
-
Hirosaki, Aomori, Japão, 036-8563
- Recrutamento
- Hirosaki University Hospital /ID# 274410
-
-
Kanagawa
-
Yokohama, Kanagawa, Japão, 221-0855
- Recrutamento
- Yokohama Municipal Citizen's Hospital /ID# 271979
-
-
Kyoto
-
Kyoto, Kyoto, Japão, 606-8507
- Recrutamento
- Kyoto University Hospital /ID# 272312
-
-
Niigata
-
Niigata, Niigata, Japão, 951-8520
- Recrutamento
- Niigata University Medical and Dental Hospital /ID# 274448
-
-
Osaka
-
Takatsuki, Osaka, Japão, 569-8686
- Recrutamento
- Osaka Medical And Pharmaceutical University Hospital /ID# 273309
-
-
Tokyo
-
Chuo-Ku, Tokyo, Japão, 104-0045
- Recrutamento
- National Cancer Center Hospital /ID# 273192
-
Koto-ku, Tokyo, Japão, 135-8550
- Recrutamento
- The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 271989
-
-
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Polônia, 20-090
- Recrutamento
- Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie /ID# 273170
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, Polônia, 15-540
- Recrutamento
- Uniwersytecki Szpital Kliniczny w Bialymstoku /ID# 276848
-
-
Pomeranian Voivodeship
-
Gdansk, Pomeranian Voivodeship, Polônia, 80-214
- Recrutamento
- Uniwersyteckie Centrum Kliniczne /ID# 272418
-
-
Świętokrzyskie Voivodeship
-
Kielce, Świętokrzyskie Voivodeship, Polônia, 25-734
- Recrutamento
- Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej /ID# 274549
-
-
-
-
-
Rio Piedras, Porto Rico, 00935
- Recrutamento
- Pan American Center for Oncology Trials - Rio Piedras /ID# 268827
-
-
-
-
-
Cardiff, Reino Unido, CF14 2TL
- Recrutamento
- Velindre Cancer Centre /ID# 271840
-
-
Leicestershire
-
Leicester, Leicestershire, Reino Unido, LE1 5WW
- Recrutamento
- University Hospitals of Leicester NHS Trust /ID# 276035
-
-
-
-
-
Bucharest, Romênia, 013975
- Recrutamento
- MNT Healthcare Europe SRL /ID# 269075
-
Bucharest, Romênia, 030171
- Recrutamento
- Spitalul Clinic Coltea /ID# 268726
-
Sibiu, Romênia, 550253
- Recrutamento
- Clinica MedLife Polisano Sibiu /ID# 269078
-
-
Cluj
-
Cluj-Napoca, Cluj, Romênia, 400080
- Recrutamento
- S.C. Radiotherapy Center Cluj SRL /ID# 268729
-
Cluj-Napoca, Cluj, Romênia, 400015
- Recrutamento
- Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca /ID# 273125
-
Cluj-Napoca, Cluj, Romênia, 400015
- Recrutamento
- Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca /ID# 268725
-
-
-
-
-
Changhua, Taiwan, 500
- Recrutamento
- Changhua Christian Hospital /ID# 280139
-
Chiayi City, Taiwan, 62247
- Recrutamento
- Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation /ID# 268789
-
Kaohsiung City, Taiwan, 807
- Recrutamento
- Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 268139
-
Kaohsiung City, Taiwan, 833
- Recrutamento
- Kaohsiung Chang Gung Memorial Hospital /ID# 268138
-
Taipei, Taiwan, 114
- Recrutamento
- Tri-Service General Hospital /ID# 269211
-
Taipei, Taiwan, 106
- Recrutamento
- National Taiwan University Cancer Center (Ntucc) /ID# 271586
-
Taipei, Taiwan, 112
- Recrutamento
- Taipei Veterans General Hospital /ID# 268787
-
Taoyuan City, Taiwan, 333
- Recrutamento
- Linkou Chang Gung Memorial Hospital /ID# 268137
-
-
-
-
-
Adana, Turquia (Türkiye), 01140
- Recrutamento
- Adana Medical Park Seyhan Hastanesi /ID# 272875
-
Ankara, Turquia (Türkiye), 06620
- Recrutamento
- Ankara Universitesi Tip Fakultesi Cebeci Hastanesi /ID# 272873
-
Ankara, Turquia (Türkiye), 06680
- Recrutamento
- Liv Hospital Ankara /ID# 272876
-
Ankara, Turquia (Türkiye), 06230
- Recrutamento
- Hacettepe Universitesi Tip Fakultesi /ID# 280631
-
Denizli, Turquia (Türkiye), 20070
- Recrutamento
- Pamukkale Universitesi /ID# 272893
-
Istanbul, Turquia (Türkiye), 34722
- Recrutamento
- Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi /ID# 280635
-
Konya, Turquia (Türkiye), 42080
- Recrutamento
- Necmettin Erbakan Universitesi Meram Tip Fakultesi - Eski Hastane /ID# 272882
-
Samsun, Turquia (Türkiye), 55139
- Recrutamento
- Ondokuz Mayis Universitesi /ID# 272899
-
Samsun, Turquia (Türkiye), 55200
- Recrutamento
- Samsun Medical Park Hastanesi /ID# 272880
-
-
Antalya
-
Ankara, Antalya, Turquia (Türkiye), 06010
- Recrutamento
- Gulhane Egitim ve Arastirma Hastanesi /ID# 280715
-
-
Sakarya
-
Adapazarı, Sakarya, Turquia (Türkiye), 54290
- Recrutamento
- Sakarya Egitim ve Arastirma Hastanesi /ID# 272878
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Must have histologically documented non-squamous (NSq) non small cell lung carcinoma (NSCLC) that is locally advanced or metastatic will be enrolled into the study.
- Must have measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.
- For Part 1, participants must have had no more than 1 systemic therapy for advanced disease including platinum-based chemotherapy or an immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy), or appropriate targeted therapy for an actionable gene alteration, if applicable, for epidermal growth factor receptor (EGFR) wild-type (WT) NSq NSCLC.
- For Part 2, participants must have no prior systemic therapy for advanced disease, no known actionable genomic alteration.
- Must have documented programmed death ligand 1 (PD-L1) status.
- For Part 2, participant must have evaluable c-Met immunohistochemistry (IHC) result per central testing prior to randomization.
- Must have adequate organ function.
Exclusion Criteria:
- Known uncontrolled metastases to the central nervous system.
- History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis on screening chest computed tomography (CT) scan.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Part 1: Telisotuzumab Adizutecan + Budigalimab
Participants will receive several doses of telisotuzumab adizutecan in combination with budigalimab, as part of the 33 month study duration. |
Intravenous (IV) Infusion
Outros nomes:
IV Infusion
Outros nomes:
|
|
Experimental: Part 2 Arm 1: Telisotuzumab Adizutecan + Pembrolizumab
Participants will receive telisotuzumab adizutecan dose A in combination with pembrolizumab, as part of the 33 month study duration. |
Intravenous (IV) Infusion
Outros nomes:
IV Injection IV Infusion |
|
Experimental: Part 2 Arm 2: Telisotuzumab Adizutecan + Pembrolizumab
Participants will receive telisotuzumab adizutecan dose B in combination with pembrolizumab, as part of the 33 month study duration. |
Intravenous (IV) Infusion
Outros nomes:
IV Injection IV Infusion |
|
Experimental: Part 2: Standard of Care
Participants will receive pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed, as part of the 33 month study duration. |
IV Infusion IV Infusion IV Injection IV Infusion IV Infusion |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Part 1: Dose-Limiting Toxicities (DLT)s of Telisotuzumab Adizutecan
Prazo: Up to Approximately 84 Days
|
DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications. |
Up to Approximately 84 Days
|
|
Part 2: Objective Response (OR) as Assessed by Blinded Independent Central Review (BICR)
Prazo: Up to Approximately 33 Months
|
OR is defined as confirmed complete response (CR) or confirmed partial response (PR) per BICR based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. |
Up to Approximately 33 Months
|
|
Number of Participants with Adverse Events (AE)s
Prazo: Up to Approximately 33 Months
|
An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. |
Up to Approximately 33 Months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Part 1 and Part 2: PFS as Assessed by Investigator
Prazo: Up to Approximately 33 Months
|
PFS is defined as the time from the participant's randomization date to the first occurrence of radiographic progression per Investigator based on RECIST v1.1 or death from any cause, whichever occurs earlier. |
Up to Approximately 33 Months
|
|
Part 1 and Part 2: DOR as Assessed by Investigator
Prazo: Up to Approximately 33 Months
|
DOR is defined as the time from the first documented CR or PR per investigator to the first occurrence of radiographic progression per the investigator on RECIST v1.1 or death from any cause, whichever occurs first. DOR is defined for participants with confirmed CR/PR. |
Up to Approximately 33 Months
|
|
Part 1 and Part 2: DC as Assessed by Investigator
Prazo: Up to Approximately 33 Months
|
DC is defined as best overall response of confirmed CR or confirmed PR, or SD for at least 11 weeks following randomization date based on RECIST v1.1, as determined by the Investigator. |
Up to Approximately 33 Months
|
|
Part 1 and Part 2: Overall Survival (OS)
Prazo: Up to Approximately 33 Months
|
OS is defined as the time from participant's randomization date (Part 2) or first dose date of study treatment (Part 1) to the event of death from any cause. |
Up to Approximately 33 Months
|
|
Programmed Death Ligand 1 (PD-L1) and c-Met Subgroups: OR
Prazo: Up to Approximately 33 Months
|
OR is defined as confirmed CR or confirmed PR based on RECIST v1.1. |
Up to Approximately 33 Months
|
|
PD-L1 and c-Met Subgroups: PFS
Prazo: Up to Approximately 33 Months
|
PFS is defined as the time from the participant's randomization date to the first occurrence of radiographic progression based on RECIST v1.1 or death from any cause, whichever occurs earlier. |
Up to Approximately 33 Months
|
|
PD-L1 and c-Met Subgroups: OS
Prazo: Up to Approximately 33 Months
|
OS is defined as the time from participant's randomization date (Part 2) or first dose date of study treatment (Part 1) to the event of death from any cause. |
Up to Approximately 33 Months
|
|
PD-L1 and c-Met Subgroups: DOR
Prazo: Up to Approximately 33 Months
|
DOR is defined as the time from the first documented CR or PR to the first occurrence of radiographic progression per RECIST v1.1 or death from any cause, whichever occurs first. DOR is defined for participants with confirmed CR/PR. |
Up to Approximately 33 Months
|
|
PD-L1 and c-Met Subgroups: DC
Prazo: Up to Approximately 33 Months
|
DC is defined as best overall response of confirmed CR or confirmed PR, or SD for at least 12 weeks following randomization date based on RECIST v1.1. |
Up to Approximately 33 Months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: ABBVIE INC., AbbVie
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Neoplasias por local
- Neoplasias
- Doenças Respiratórias
- Doenças pulmonares
- Neoplasias do Trato Respiratório
- Neoplasias Torácicas
- Neoplasias Pulmonares
- Carcinoma Broncogênico
- Neoplasias Brônquicas
- Carcinoma pulmonar de células não pequenas
- Aminoácidos, peptídeos e proteínas
- Produtos químicos orgânicos
- Compostos heterocíclicos
- Compostos heterocíclicos, 2 anel
- Compostos heterocíclicos, anel fundido
- Produtos químicos inorgânicos
- Compostos de cloro
- Compostos de nitrogênio
- Complexos de coordenação
- Guanina
- Hipoxantinas
- Purinonas
- Purinas
- Glutamatos
- Aminoácidos, ácido
- Aminoácidos
- Aminoácidos, dicarboxílico
- Compostos de platina
- Pemetrexede
- Carboplatina
- Cisplatina
- Pembrolizumab
- Budigalimab
Outros números de identificação do estudo
- M24-536
- 2024-514465-18 (Outro identificador: EU CT)
- 2024-514465-18-00 (Ctis)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Prazo de Compartilhamento de IPD
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Critérios de acesso de compartilhamento IPD
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .